logo
Families of Revere women who died in Belize call for ‘transparent' investigation

Families of Revere women who died in Belize call for ‘transparent' investigation

Boston Globe10-03-2025

'The circumstances surrounding this tragedy remain unclear and suspicious, and we are seeking answers to understand what happened in Belize,' the families said in a statement issued on their
Authorities in Belize have said the women appeared to have froth been frothing at their mouths and investigators found alcohol and 'gummies' in the room. There was no sign of forced entry or injuries.
Advertisement
In the statement, relatives recalled each of the women.
Wafae El Arar
'was full of life, dreams, and unwavering faith. Her name, meaning faithfulness and loyalty, was a true reflection of who she was — honest, kind, and deeply devoted to the people she loved,' relatives said. She was 'on a personal journey of faith, planning to wear the hijab this Ramadan alongside her younger sister.'
Wafae El Arar cuts a cake in celebration of her graduation. (Family Photo)
Family Photo
El Arar graduated from Revere High School in 2017 and Stonehill College in 2021 with a degree in biochemistry, according to her LinkedIn profile.
El Arar was a research technician at the Mitchell Lab at Massachusetts General Hospital focused on women's health. She was 'committed to making a difference in an area often overlooked in healthcare,' relatives said.
'She was so proud to have recently
Advertisement
Imane Mallah 'had a unique ability to listen deeply, making everyone feel heard and valued,' relatives said. 'She was a radiant spirit, and a beacon of kindness. She embraced life wholeheartedly, cherishing every soul that shared the journey with her.'
Her friends considered her 'a warm, comforting light, guiding them through even the darkest of times,' the family wrote. She was a graduate of Revere High School.
Imane Mallah. (Family Photo)
Family Photo
Mallah worked with Phoenix Protective Service, a Charlestown-based security firm, according to a
Her family wrote that 'Imane poured her heart into everything she did. Her laughter was contagious, and her stories were filled with humor and wisdom, leaving those around her both entertained and inspired ... She was our greatest love and we will miss her every day for the rest of our lives.'
Kaoutar Naqqad was 'the light in our lives, someone whose kindness and warmth touched everyone she met,' her relatives said. 'As the youngest daughter of four siblings, she held a special place in our family, bringing joy, laughter, and love into our home every single day.'
She was attending college and also worked at a group home for 'troubled youth,' her family wrote. Her professional goal was to become part of law enforcement.
Kaoutar Naqqad. (Family Photo)
Family Photo
Naqqad, also a graduate of Revere High School, had taken the civil service exam and recently took the civil service exam for the State Police.
Advertisement
Naqqad had a fear of flying but set that aside to visit Belize with her two close friends. She was planning to visit Morocco with her parents this summer, according to relatives.
'Her heart was full of generosity, always putting others before herself and offering a listening ear, a comforting word, and unwavering support,' the family wrote. 'We cannot put into words the depth of our grief and the void that Kaoutar's passing has left in our hearts.'
The families expressed thanks for the outpouring of support they have received in Revere and among the Muslim and Moroccan communities in the area.
'We ask for continued prayers, patience, and privacy as we navigate this profound sorrow,' they said. 'May their beautiful souls rest in eternal peace.'
John R. Ellement can be reached at

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

China's Center for Drug Evaluation Accepts Merck KGaA, Darmstadt, Germany's Application for Marketing Authorization of Pimicotinib for Treatment of Tenosynovial Giant Cell Tumor
China's Center for Drug Evaluation Accepts Merck KGaA, Darmstadt, Germany's Application for Marketing Authorization of Pimicotinib for Treatment of Tenosynovial Giant Cell Tumor

Yahoo

time30 minutes ago

  • Yahoo

China's Center for Drug Evaluation Accepts Merck KGaA, Darmstadt, Germany's Application for Marketing Authorization of Pimicotinib for Treatment of Tenosynovial Giant Cell Tumor

First global filing for potentially best-in-class TGCT treatment based on strong positive data from Phase 3 MANEUVER study Potential for pimicotinib to be first systemic TGCT therapy approved in China, following recent granting of Priority Review by CDE Additional applications planned in the US and other markets around the world Not intended for UK-based media DARMSTADT, Germany, June 10, 2025--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) officially accepted the company's application for marketing authorization of pimicotinib as a Class 1 innovative drug for adult patients with tenosynovial giant cell tumors (TGCT) requiring systemic treatment. The submission follows the granting of Priority Review to pimicotinib by the CDE in May for the treatment of patients with TGCT who require systemic therapy, which is expected to expedite the review process. Pimicotinib, a potentially best-in-class investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., also has been granted breakthrough therapy designation (BTD) by the NMPA. "With the acceptance of our application for pimicotinib and the initiation of the priority review, we aim to offer patients in China the first approved systemic therapy for TGCT, addressing a tremendous unmet need in this country," said Hong Chow, Head of China and International, Healthcare business of Merck KGaA, Darmstadt, Germany. "Pimicotinib has demonstrated the ability to not only shrink tumors that affect their joints but also improve outcomes like mobility, pain and stiffness, highlighting its potential to be a best-in-class treatment for TGCT. In parallel, we are working to file a New Drug Application to the US Food and Drug Administration, with additional filings planned in other markets." TGCT is a locally aggressive and often recurring tumor of the joints that can cause high morbidity associated with swelling, pain, stiffness, and limited mobility of the affected joints, significantly impacting daily activities and quality of life in the primarily working-age population that it affects. If left untreated or in recurrent cases, TGCT can result in irreversible damage to the bone, joint and surrounding tissues. This highlights the need for well-tolerated and effective systemic treatments that can impact tumor growth while relieving the symptoms of the disease. The application is based on results from Part 1 of the global Phase 3 MANEUVER study, in which once-daily pimicotinib demonstrated a statistically significant improvement in the primary endpoint of objective response rate (ORR) assessed by blinded independent review committee (BIRC) compared with placebo at week 25 (54.0% vs. 3.2% for placebo; p<0.0001). The study also demonstrated statistically significant and clinically meaningful improvements in all secondary endpoints related to key patient-reported outcomes in TGCT, including improvements in active range of motion and physical function and reductions in stiffness and pain. The data were presented earlier this month at the 2025 ASCO Annual Meeting. About MANEUVERThe pivotal Phase 3 MANEUVER study is a three-part, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of pimicotinib in patients with TGCT who require systemic therapy and have not received prior anti-CSF-1/CSF-1R therapy. The study is being conducted by Abbisko Therapeutics in China (n=45), Europe (n=28), and the US and Canada (n=21). In the double-blind Part 1, 94 patients were randomized 2:1 to receive either 50 mg QD of pimicotinib (n=63) or placebo (n=31) for 24 weeks. The primary endpoint is objective response rate (ORR) at week 25, as measured by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by blinded independent central review in the intent-to-treat (ITT) population. Secondary endpoints include tumor volume score, active range of motion, stiffness by Numeric Rating Scale (NRS), pain by Brief Pain Inventory (BPI), and physical function measured by Patient-Reported Outcomes Measurement Information System (PROMIS). After the double-blind Part 1, eligible patients could continue to the open-label Part 2 for up to 24 weeks of dosing, results of which are expected in mid-2025. Patients who complete Part 2 may then enter the open-label extension phase (Part 3) for extended treatment and safety follow-up. About Pimicotinib (ABSK021)Pimicotinib (ABSK021), which is being developed by Abbisko Therapeutics, is a novel, orally administered, highly selective and potent small-molecule inhibitor of CSF-1R. Pimicotinib was recently granted Priority Review by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) for the treatment of patients with tenosynovial giant cell tumor (TGCT) who require systemic therapy. Pimicotinib has been granted breakthrough therapy designation (BTD) by China National Medical Products Administration (NMPA) and the US Food and Drug Administration (FDA), and priority medicine (PRIME) designation from the European Medicines Agency (EMA). Merck KGaA, Darmstadt, Germany, holds worldwide commercialization rights for pimicotinib. Advancing the Future of Cancer CareAt Merck KGaA, Darmstadt, Germany, we strive every day to improve the futures of people living with cancer. Building on our 350-year global heritage as pharma pioneers, we are focusing our most promising science to target cancer's deepest vulnerabilities, pursuing differentiated molecules to strike cancer at its core. By developing new therapies that can help advance cancer care, we are determined to create a world where more cancer patients will become cancer survivors. Learn more at About Merck KGaA, Darmstadt, GermanyMerck KGaA, Darmstadt, Germany, a leading science and technology company, operates across life science, healthcare and electronics. More than 62,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2024, Merck KGaA, Darmstadt, Germany, generated sales of € 21.2 billion in 65 countries. The company holds the global rights to the name and trademark "Merck" internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare and EMD Electronics in electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company's technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group website. In case you are a resident of the USA or Canada, please go to to register for your online, change your selection or discontinue this service. View source version on Contacts Media Relations Phone: +1 (781) 427-4351 Investor Relations Phone: +49 6151 72-3321 Sign in to access your portfolio

MemoDefend Announces Official Website Update Featuring Natural Daily Supplement for Cognitive Support
MemoDefend Announces Official Website Update Featuring Natural Daily Supplement for Cognitive Support

Yahoo

time36 minutes ago

  • Yahoo

MemoDefend Announces Official Website Update Featuring Natural Daily Supplement for Cognitive Support

Natural Brain Health Formula Now Available Online to Support Memory, Focus, and Cognitive Function in Adults Lakeland, June 09, 2025 (GLOBE NEWSWIRE) -- MemoDefend, a Florida-based wellness brand, has updated its official website to provide consumers with new information about its daily supplement formulated to support cognitive clarity and brain function in adults. Now available nationwide, the natural memory support formula is designed for individuals seeking a consistent, easy-to-integrate wellness solution. According to the official product website ( MemoDefend is intended to work in harmony with the body's internal processes to support healthy memory retention, mental sharpness, and overall cognitive performance. The brand highlights its approach as one that simplifies brain wellness without requiring restrictive regimens or complicated routines. 'We developed MemoDefend to help adults support brain health naturally—without disrupting their lifestyle,' said a company spokesperson. 'This product reflects our focus on purity, simplicity, and long-term wellness.' The company states that MemoDefend is produced in facilities that follow strict quality control practices. Its formulation features a selection of ingredients that align with adult wellness priorities such as cognitive support, mental clarity, and healthy aging. As noted on the website, MemoDefend includes a satisfaction guarantee for new customers. Those interested in learning more about its intended use or placing an order can find full details, customer support access, and purchasing options directly at the official website. About MemoDefend MemoDefend is a Lakeland, Florida-based wellness brand committed to delivering natural, easy-to-use supplements that support everyday health routines. Focused on transparency and simplicity, the company develops formulas to help adults feel more confident in their wellness journey—one daily step at a time. Product and Contact Information Brand: MemoDefendWebsite: support@ +1 (888) 535-1590Mailing Address: P.O. Box 90129, Lakeland, FL 33804, United States Disclaimer This release is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. The statements made about this product have not been evaluated by the Food and Drug Administration. Individual results may vary. Consumers should consult a qualified healthcare provider before beginning any new dietary supplement. CONTACT: Email: support@ Phone: +1 (888) 535-1590Sign in to access your portfolio

UnitedHealth Group received multiple bids for Latin American operations
UnitedHealth Group received multiple bids for Latin American operations

Yahoo

timean hour ago

  • Yahoo

UnitedHealth Group received multiple bids for Latin American operations

-- UnitedHealth Group (NYSE:UNH) is considering several offers for its Latin American operations, according to a Reuters report on Monday. The move comes as the largest U.S. health insurer faces challenges that include the departure of its CEO and an alleged criminal accounting investigation. The insurer has been attempting to leave Latin America since 2022, with the sale of its Banmedica subsidiary becoming more urgent in recent months due to increasing pressures on multiple fronts, the report said. So far, UnitedHealth has reportedly received four preliminary bids for Banmedica, which operates in Colombia and Chile, with an estimated value of about $1 billion. In May, UnitedHealth's shares dropped 25.5%, and the year-to-date decline stands at 40%. The company withdrew from Brazil in 2023 and from Peru in March 2025. It aims to secure around $1 billion for Banmedica's operations in Colombia and Chile. The company anticipates setting a deadline for final proposals as early as July. The bids reportedly include offers from Washington, D.C.-based private equity firm Acon Investments, Sao Paulo-based private equity firm Patria Investments, Texas non-profit health organization Christus Health, and Lima-based healthcare and insurance provider Auna. The report mentioned that Auna is currently in discussions with a financial partner. Related articles UnitedHealth Group received multiple bids for Latin American operations Tesla shares slip after double downgrade amid Trump feud fallout What are the three big things in markets now? RBC weighs in

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store